Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs

Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15 years, are limited in their clinical application due to serious side effects. Therefore, we converted two approved TKIs (sunitinib and erlotinib) into 2-nitroimidazole-based hypoxia-activatable prodrugs. Kin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ChemMedChem
Main Authors: Karnthaler-Benbakka, Claudia, Groza, Diana, Koblmüller, Bettina, Terenzi, Alessio, Holste, Katharina, Haider, Melanie, Baier, Dina, Berger, Walter, Heffeter, Petra, Kowol, Christian R., Keppler, Bernhard K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151264/
https://ncbi.nlm.nih.gov/pubmed/27706901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cmdc.201600417
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados